

Islam M Miligy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/106887/publications.pdf>

Version: 2024-02-01

41
papers

953
citations

393982

19
h-index

476904

29
g-index

43
all docs

43
docs citations

43
times ranked

1484
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons from a breast cell annotation competition series for school pupils. <i>Scientific Reports</i> , 2022, 12, 7792.	1.6	1
2	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. <i>Pathobiology</i> , 2022, 89, 382-392.	1.9	1
3	Diagnostic concordance and discordance in digital pathology: a systematic review and meta-analysis. <i>Journal of Clinical Pathology</i> , 2021, 74, 448-455.	1.0	48
4	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. <i>Theranostics</i> , 2021, 11, 8350-8361.	4.6	10
5	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. <i>Modern Pathology</i> , 2021, 34, 1271-1281.	2.9	43
6	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥ 2.0 , HER2) Tj ETQp 0 0 rgBT /Overloc		
7	Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. <i>Oncogene</i> , 2021, 40, 2496-2508.	2.6	12
8	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. <i>Cancers</i> , 2021, 13, 1866.	1.7	12
9	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 53-63.	1.1	4
10	The frequency and clinical significance of DNA polymerase beta (POL β) expression in breast ductal carcinoma in situ (DCIS). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 39-51.	1.1	1
11	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. <i>Cancer Letters</i> , 2020, 469, 124-133.	3.2	22
12	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 79-90.	1.1	18
13	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. <i>Journal of Clinical Pathology</i> , 2020, 73, 76-82.	1.0	31
14	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 557-564.	1.1	13
15	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 123, 1513-1520.	2.9	4
16	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 541-551.	1.1	22
17	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 122, 1496-1506.	2.9	26
18	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. <i>Npj Breast Cancer</i> , 2020, 6, 9.	2.3	19

#	ARTICLE	IF	CITATIONS
19	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>in Situ</i> . <i>Clinical Cancer Research</i> , 2020, 26, 2898-2907.	3.2	4
20	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 267-282.	1.1	58
21	Abstract P6-10-21: Evaluation of genomic changes in ductal carcinoma <i>in situ</i> as potential biomarkers of recurrence risk. , 2020, , .		0
22	Surgical management of ductal carcinoma <i>in situ</i> of the breast: A large retrospective study from a single institution. <i>Breast Journal</i> , 2019, 25, 1143-1153.	0.4	7
23	A whole slide image-based machine learning approach to predict ductal carcinoma <i>in situ</i> (DCIS) recurrence risk. <i>Breast Cancer Research</i> , 2019, 21, 83.	2.2	39
24	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p53 Deficient Cancer Cells and Influence Platinum Sensitivity. <i>Cells</i> , 2019, 8, 1271.	1.8	12
25	Collagen (XII) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma <i>in situ</i> . <i>Modern Pathology</i> , 2019, 32, 1460-1472.	2.9	23
26	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma <i>in situ</i> : an image analysis study. <i>Modern Pathology</i> , 2019, 32, 1473-1485.	2.9	11
27	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma <i>in situ</i> : a large study from a single institution. <i>British Journal of Cancer</i> , 2019, 120, 1075-1082.	2.9	27
28	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. <i>Journal of Pathology</i> , 2019, 248, 326-338.	2.1	21
29	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma <i>in situ</i> . <i>Histopathology</i> , 2019, 74, 1025-1035.	1.6	16
30	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 387-399.	1.1	53
31	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma <i>in situ</i> . <i>Modern Pathology</i> , 2019, 32, 639-649.	2.9	19
32	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma <i>in situ</i> of the breast. <i>Modern Pathology</i> , 2018, 31, 1226-1236.	2.9	56
33	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	1.6	25
34	Prolyl-4-hydroxylase β subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma <i>in situ</i> (DCIS). <i>British Journal of Cancer</i> , 2018, 119, 1518-1526.	2.9	32
35	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>in Situ</i> Induces Synthetic Lethality and Chemoprevention. <i>Cancer Research</i> , 2018, 78, 6818-6827.	0.4	26
36	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma <i>in situ</i> . <i>Modern Pathology</i> , 2018, 31, 1807-1815.	2.9	23

#	ARTICLE	IF	CITATIONS
37	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. <i>Breast Cancer Research</i> , 2018, 20, 21.	2.2	85
38	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma <i>in situ</i> . <i>Histopathology</i> , 2017, 71, 258-268.	1.6	58
39	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. <i>Breast</i> , 2017, 35, 151-156.	0.9	24
40	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 493-502.	1.4	30
41	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 404.	0.6	5